Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
- Symbol
- EBS
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $342.17M
- 52 week range
- 4.36 - 14.06
Valuation
- Share price
- $6.67 (close of 2026-09-23)
- P/E (TTM)
- -1.96x
- Price to book
- 1.00x
- Price to free cash flow
- 3.98x
- Enterprise value
- $784.27M
- Book value per share
- $6.65
Price performance
| Period | Change |
|---|
| 1 day | +1.83% |
| 5 days | +4.87% |
| 1 month | +31.30% |
| 3 months | -16.73% |
| 6 months | -17.14% |
| Year to date | -46.04% |
| 1 year | -18.46% |
| 3 years | +104.60% |
| 5 years | -87.61% |
| 10 years | -76.48% |
| All time | -42.99% |
Profitability and growth
- Return on equity
- 10.07%
- Return on invested capital
- 7.86%
- Return on assets
- 3.99%
- Return on capital employed
- 8.44%
- Gross margin
- 56.09%
- Net margin
- 7.08%
- EBITDA margin
- 26.37%
- Revenue growth
- -28.81%
- Net income growth
- 127.60%
- Free cash flow growth
- 337.99%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 25.10%
- Current ratio
- 5.42x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $742.90M
- Cost of revenue
- $326.20M
- Gross profit
- $416.70M
- EBITDA
- $195.90M
- Net income
- $52.60M
- Earnings per share
- $0.98
- Research and development
- $53.20M
- Shares outstanding
- 53.50M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $742.90M | $416.70M | $52.60M | $0.98 |
| 2024-12-31 | $1.04B | $362.30M | $-190.60M | $-3.60 |
| 2023-12-31 | $1.05B | $317.60M | $-760.50M | $-14.85 |
| 2022-12-31 | $1.12B | $383.00M | $-211.60M | $-4.22 |
| 2021-12-31 | $1.77B | $891.30M | $219.50M | $4.10 |
| 2020-12-31 | $1.56B | $925.20M | $305.80M | $5.80 |
| 2019-12-31 | $1.11B | $672.50M | $54.50M | $1.06 |
| 2018-12-31 | $782.40M | $460.10M | $62.70M | $1.25 |
| 2017-12-31 | $560.90M | $373.20M | $82.60M | $1.98 |
| 2016-12-31 | $488.80M | $362.50M | $51.80M | $1.29 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 56.09% | 7.08% | 10.07% | 7.86% |
| 2024-12-31 | 34.72% | -18.26% | -39.48% | -10.38% |
| 2023-12-31 | 30.27% | -72.48% | -117.13% | -51.97% |
| 2022-12-31 | 34.27% | -18.94% | -15.25% | -7.56% |
| 2021-12-31 | 50.25% | 12.38% | 13.62% | 13.52% |
| 2020-12-31 | 59.48% | 19.66% | 21.08% | 19.13% |
| 2019-12-31 | 60.80% | 4.93% | 4.99% | 5.18% |
| 2018-12-31 | 58.81% | 8.01% | 6.20% | 4.19% |
| 2017-12-31 | 66.54% | 14.73% | 9.05% | 11.81% |
| 2016-12-31 | 74.16% | 10.60% | 8.69% | 12.01% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $205.40M | $572.10M |
| 2024-12-31 | $99.50M | $663.70M |
| 2023-12-31 | $111.70M | $446.50M |
| 2022-12-31 | $642.60M | $448.50M |
| 2021-12-31 | $576.10M | $809.40M |
| 2020-12-31 | $621.30M | $841.00M |
| 2019-12-31 | $167.80M | $798.40M |
| 2018-12-31 | $112.20M | $784.50M |
| 2017-12-31 | $178.30M | $13.50M |
| 2016-12-31 | $271.50M | $248.09M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $156.80M | $16.20M |
| 2024-12-31 | $35.80M | $18.00M |
| 2023-12-31 | $-257.90M | $23.10M |
| 2022-12-31 | $-149.90M | $45.10M |
| 2021-12-31 | $96.10M | $42.40M |
| 2020-12-31 | $395.00M | $51.80M |
| 2019-12-31 | $101.10M | $26.70M |
| 2018-12-31 | $-30.30M | $23.20M |
| 2017-12-31 | $153.30M | $15.20M |
| 2016-12-31 | $-21.60M | $18.50M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | - |
| 2026-04-30 | - | - |
| 2026-02-26 | - | - |
| 2025-10-29 | - | - |
| 2025-08-06 | - | - |
| 2025-05-07 | - | - |
| 2025-04-29 | - | - |
| 2025-03-04 | - | - |
Filings and sources
- Company website
- emergentbiosolutions.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades